Press Releases

Onxeo announces development of Beleodaq® oral formulation opening new opportunities for its HDAC inhibitor // DANISH TRANSLATION: Onxeo offentliggør udviklingen af en oral formulering af Beleodaq®, som åbner nye muligheder for selskabets HDAC-hæmmer

NB! FOR DANISH TRANSLATION, SCROLL DOWN. The company has obtained the first set of positive results of PK study with new oral formulation of Beleodaq®  Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced the first set of positive results from a preclinical pharmacokinetic (PK)…read more →

Publication of 2015 Reference Document // DANISH TRANSLATION: Offentliggørelse af Reference Document for 2015

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced the publication of the Company’s 2015 Reference Document. The 2015 Reference Document, registered with the French Market Authorities (Autorité des Marchés Financiers) on April 29, 2016, is available to the…read more →

Onxeo First Quarter 2016 Financial Information and Business Update // DANISH TRANSLATION: Onxeo informerer om sine resultater og forretningsmæssige tiltag i 1. kvartal 2016

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Pipeline reinforced through major development milestones on existing assets and new product acquisition Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today provided an update on financial results and major milestones achieved during the first quarter of 2016, ending March…read more →

Onxeo Final Data from Mechanistic Livatag® Study Show Preferential Affinity for Liver, Support Use as Advanced HCC Treatment // DANISH TRANSLATION: Endelige data fra mekanistisk studie med Livatag® viser foretrukken affinitet for leveren, hvilket understøtter brugen til behandling af fremskreden HCC

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Full results presented at AACR Annual Meeting 2016 Support continued evaluation of Livatag® in ongoing Phase III ReLive Trial  Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today reported the final data from a study aiming to confirm the mechanism…read more →

Passing on Onxeo’s Extraordinary and Ordinary General Meeting // DANISH TRANSLATION: Forløb af Onxeos ekstraordinære og ordinære generalforsamling

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced that the Extraordinary and Ordinary General Meeting, held at the company’s headquarters in Paris, France on April 6, 2016, adopted all of the resolutions recommended by the Board of Directors….read more →

Onxeo announces positive DSMB recommendation to continue Livatag® ReLive study in HCC // DANISH TRANSLATION: Onxeo offentliggør positiv anbefaling fra DSMB om at fortsætte ReLive-studiet med Livatag® mod leverkræft

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Paris (France), Copenhagen (Denmark),  – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced that it has received a unanimous recommendation from the Data Safety Monitoring Board (DSMB), the independent European board of experts that monitors the safety of the Livatag® Phase III…read more →

Onxeo announces closing of DNA Therapeutics acquisition // DANISH TRANSLATION: Onxeo gennemfører opkøbet af DNA Therapeutics

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Onxeo gains access to AsiDNA compound, a first-in-class signal interfering DNA Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced that it has completed the acquisition of DNA Therapeutics and its signal-interfering DNA (siDNA) repair technology and lead product…read more →

Onxeo Announces Establishment of U.S. Subsidiary // DANISH TRANSLATION: Onxeo etablerer amerikansk datterselskab

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Pharmaceutical and biotech industry veteran, Philippe Maitre, to head U.S subsidiary Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced the creation of a U.S. subsidiary, based in New York City. The company also announced that experienced industry executive…read more →

Onxeo Poster Demonstrating Unique Livatag® Mechanism of Action Accepted for Presentation at AACR Annual Meeting // DANISH TRANSLATION: Onxeo-poster godkendt til præsentation på årsmødet i AACR: Livatag® demonstrerer unik virkningsmekanisme

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced that a poster demonstrating the unique mechanism of action of Livatag® has been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, one of the…read more →

Onxeo Ordinary and Extraordinary General Meeting on April 6, 2016 // DANISH TRANSLATION: Onxeo ordinær og ekstraordinær generalforsamling den 6. april 2016

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Paris (France), Copenhagen (Denmark) –  Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced that Onxeo’s shareholders are invited to attend the Company’s Combined Ordinary and Extraordinary General Meeting which is being held on April 6, 2016 at 10.00 AM CET at Onxeo’s headquarters:…read more →

Onxeo announces acquisition of DNA Therapeutics and provides update on Validive® development plan // DANISH TRANSLATION: Onxeo offentliggør opkøb af DNA Therapeutics og giver en opdatering om udviklingsplanen for Validive®

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Onxeo acquires first-in-class, signal-interfering DNA molecule based on one of the most promising new approaches in cancer treatment  Acquisition expands Company’s R&D pipeline and opens new opportunities in orphan oncology indications Further development of Validive® to be conducted in partnership Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company…read more →

Onxeo Reports 2015 Full-Year Results and Provides Business Update // DANISH TRANSLATION: Onxeo offentliggør resultat for helåret 2015 og opdaterer om virksomheden

NB! FOR DANISH TRANSLATION, SCROLL DOWN. 2015: Successful year of consolidation and major achievements in all lead programs Progression of Phase III trial of Livatag® in HCC in line with development calendar; positive results of Phase I trial of Beleodaq® and CHOP in 1st-line PTCL New preclinical development program of lead products in combination with immunotherapy and other cancer agents…read more →

Onxeo expands collaborations to advance development program of key orphan oncology assets in combination with immuno-oncology agents // DANISH TRANSLATION: Onxeo udvider sine samarbejdsaftaler for at videreudvikle sit program med væsentlige aktiver inden for sjældne kræftsygdomme i kombination med immune-onkologiske stoffer

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Following first positive results already obtained  in several types of tumors  New partnership with CIMA’s Immunology Program and the Liver Unit at Clinica Universidad de Navarra in Spain under the leadership of Prof. B. Sangro Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan…read more →

Onxeo to attend upcoming investor conferences and medical meetings // DANISH TRANSLATION: Onxeo deltager i kommende investormøder og videnskabelige konferencer

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced that senior management will present updates on the Company’s advanced orphan oncology pipeline at the following upcoming investor conferences: ODDO Biotech / Medtech Forum – March 31, 2016 in Paris…read more →

Onxeo announces the evolution and reinforcement of its Board of Directors // DANISH TRANSLATION: Onxeo udvider og styrker bestyrelsen

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Drs. Jean-Pierre Kinet of Harvard Medical School, and Jean-Pierre Bizzari, international expert in Oncology, join the Onxeo Board of Directors as Board Observers Joseph Zakrzewski elected as Onxeo Chairman Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, announced that…read more →